BACKGROUND: The Hippo pathway is a developmental pathway recently discovered in Drosophila melanogaster; in mammals it normally controls organ development and wound healing. Hippo signaling is deregulated in breast cancer (BC). MST1/2 and LATS1/2 kinases are the upstream molecular elements of Hippo signaling which phosphorylate and regulate the two effectors of Hippo signaling, YAP1 and TAZ cotranscriptional activators. The two molecular effectors of the Hippo pathway facilitate their activity through TEAD transcription factors. Several molecular pathways with known oncogenic functions cross-talk with the Hippo pathway. METHODS: A systematic review studying the correlation of the Hippo pathway with BC tumorigenesis, prognosis, and treatment was performed. RESULTS: Recent literature highlights the critical role of Hippo signaling in a wide spectrum of biological mechanisms in BC. DISCUSSION: The Hippo pathway has a crucial position in BC molecular biology, cellular behavior, and response to treatment. Targeting the Hippo pathway could potentially improve the prognosis and outcome of BC patients.
BACKGROUND: The Hippo pathway is a developmental pathway recently discovered in Drosophila melanogaster; in mammals it normally controls organ development and wound healing. Hippo signaling is deregulated in breast cancer (BC). MST1/2 and LATS1/2 kinases are the upstream molecular elements of Hippo signaling which phosphorylate and regulate the two effectors of Hippo signaling, YAP1 and TAZ cotranscriptional activators. The two molecular effectors of the Hippo pathway facilitate their activity through TEAD transcription factors. Several molecular pathways with known oncogenic functions cross-talk with the Hippo pathway. METHODS: A systematic review studying the correlation of the Hippo pathway with BC tumorigenesis, prognosis, and treatment was performed. RESULTS: Recent literature highlights the critical role of Hippo signaling in a wide spectrum of biological mechanisms in BC. DISCUSSION: The Hippo pathway has a crucial position in BC molecular biology, cellular behavior, and response to treatment. Targeting the Hippo pathway could potentially improve the prognosis and outcome of BC patients.
Authors: He Shen; Nuo Yang; Alexander Truskinovsky; Yanmin Chen; Ashley L Mussell; Norma J Nowak; Lester Kobzik; Costa Frangou; Jianmin Zhang Journal: Mol Cancer Res Date: 2018-09-20 Impact factor: 5.852
Authors: Anna Di Benedetto; Marcella Mottolese; Francesca Sperati; Cristiana Ercolani; Luigi Di Lauro; Laura Pizzuti; Patrizia Vici; Irene Terrenato; Abeer M Shaaban; Matthew P Humphries; Sreekumar Sundara-Rajan; Maddalena Barba; Valerie Speirs; Ruggero De Maria; Marcello Maugeri-Saccà Journal: J Cell Physiol Date: 2017-03-03 Impact factor: 6.384
Authors: Dafni-Eleftheria Pefani; Daniela Pankova; Aswin G Abraham; Anna M Grawenda; Nikola Vlahov; Simon Scrace; Eric O' Neill Journal: Mol Cell Date: 2016-06-09 Impact factor: 17.970
Authors: Helena J Janse van Rensburg; Taha Azad; Min Ling; Yawei Hao; Brooke Snetsinger; Prem Khanal; Lori M Minassian; Charles H Graham; Michael J Rauh; Xiaolong Yang Journal: Cancer Res Date: 2018-01-16 Impact factor: 12.701
Authors: Cheng Chang; Hira Lal Goel; Huijie Gao; Bryan Pursell; Leonard D Shultz; Dale L Greiner; Sulev Ingerpuu; Manuel Patarroyo; Shiliang Cao; Elgene Lim; Junhao Mao; Karen Kulju McKee; Peter D Yurchenco; Arthur M Mercurio Journal: Genes Dev Date: 2015-01-01 Impact factor: 11.361
Authors: Simran Kaur; Mohammad Zeeshan Najm; Mohammad Aasif Khan; Naseem Akhter; Vyas M Shingatgeri; Mudra Sikenis; Abdulaziz A Aloliqi Journal: Breast Cancer (Dove Med Press) Date: 2021-12-14